Midostaurin has been approved by the FDA for the treatment of newly diagnosed adult patients with mutant FLT3-positive AML and adult patients with systemic mastocytosis with associated hematological neoplasm or mast cell leukemia, which is an aggressive subtype of AML [7]. Here, FLT3 is linked to acute myeloid leukemia.